Latest Breaking News On - Leukemia society of america - Page 5 : comparemela.com

(0) Initiates Multi-Center, Multi-Arm Trial Using Active Dose Identified in the Dose Escalation Phase of the Trial SEATTLE, WA / ACCESSWIRE / May 27, 2021 / Aptevo Therapeutics Inc. ( Aptevo ) (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR TM and ADAPTIR-FLEX TM platform technologies today announced that the company has initiated the expansion phase of lead anti-leukemia drug candidate, APVO436, in adult patients with acute myeloid leukemia (AML) with a multi-center, multi-arm trial using the active recommended dose identified in the dose escalation phase (Part 1) of the study. During Part 1, APVO436 exhibited a manageable side effect profile, encouraging single agent activity and a promising benefit to risk profile in relapsed AML patients. The Company has plans to submit data from the dose escalation phase for publication later this year.

United statesFatih uckunJustin wattsMarvin whiteExchange commissionAptevo therapeutics incUniversity of miami sylvester comprehensive cancer centerLeukemia lymphoma society scholarLeukemia society of americaInitiates multi centerMulti arm trial using active dose identifiedDose escalation phaseAptevo therapeuticsChief clinicalAssociate professorMiami sylvester comprehensive cancer